Literature DB >> 30782307

Below the Biologically Effective Dose.

Christoph Glanzmann, Gabriela Studer.   

Abstract

Mesh：

Year:  2019        PMID： 30782307      PMCID： PMC6384515          DOI： 10.3238/arztebl.2019.0009c

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  4 in total

1.  Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial.

Authors:  J Roger Owen; Anita Ashton; Judith M Bliss; Janis Homewood; Caroline Harper; Jane Hanson; Joanne Haviland; Soren M Bentzen; John R Yarnold
Journal:  Lancet Oncol       Date:  2006-06       Impact factor: 41.316

2.  The Screening, Diagnosis, Treatment, and Follow-Up of Breast Cancer.

Authors:  Achim Wöckel; Ute-Susann Albert; Wolfgang Janni; Anton Scharl; Rolf Kreienberg; Tanja Stüber
Journal:  Dtsch Arztebl Int       Date:  2018-05-04       Impact factor: 5.594

3.  Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation.

Authors:  Joanne S Haviland; Søren M Bentzen; Judith M Bliss; John R Yarnold
Journal:  Radiother Oncol       Date:  2016-09-22       Impact factor: 6.280

4.  The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

Authors:  Joanne S Haviland; J Roger Owen; John A Dewar; Rajiv K Agrawal; Jane Barrett; Peter J Barrett-Lee; H Jane Dobbs; Penelope Hopwood; Pat A Lawton; Brian J Magee; Judith Mills; Sandra Simmons; Mark A Sydenham; Karen Venables; Judith M Bliss; John R Yarnold
Journal:  Lancet Oncol       Date:  2013-09-19       Impact factor: 41.316
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.